Earnings
10x Genomics Lifts 2026 Sales Outlook To $625 Million–$635 Million As Quarterly Loss Narrows
Consumables sales increased while instrument revenue fell, and lower inventory markdowns helped improve gross margin.
10x Genomics (TXG) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Consumables sales increased while instrument revenue fell, and lower inventory markdowns helped improve gross margin.
Earnings
The CEO said building and installing the new instrument is the limit, and the CFO warned fourth-quarter gross margin falls from 75%.
SEC Filings
Ansuman Satpathy and Joseph Gilliam joined the board as Class III directors, and Gilliam now chairs the audit committee.
SEC Filings
The passive-ownership amendment lists an event date of September 30, with most voting power held solely by ARK.